These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36460267)

  • 1. Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.
    Sung ML; Viera A; Esserman D; Tong G; Davidson D; Aiudi S; Bailey GL; Buchanan AL; Buchelli M; Jenkins M; John B; Kolakowski J; Lame A; Murphy SM; Porter E; Simone L; Paris M; Rash CJ; Edelman EJ
    Contemp Clin Trials; 2023 Feb; 125():107037. PubMed ID: 36460267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
    Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
    Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol for an efficacy trial of the "PrEP for Health" intervention to increase HIV PrEP use among people who inject drugs.
    Bazzi AR; Bordeu M; Baumgartner K; Sproesser DM; Bositis CM; Krakower DS; Mimiaga MJ; Biello KB
    BMC Public Health; 2023 Mar; 23(1):513. PubMed ID: 36932369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.
    Shrestha R; Altice FL; Sibilio B; Ssenyonjo J; Copenhaver MM
    Contemp Clin Trials; 2019 Jul; 82():77-84. PubMed ID: 31229618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.
    Biello KB; Bazzi AR; Mimiaga MJ; Biancarelli DL; Edeza A; Salhaney P; Childs E; Drainoni ML
    Harm Reduct J; 2018 Nov; 15(1):55. PubMed ID: 30419926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Provider Implicit Bias in Prescribing HIV Pre-exposure Prophylaxis (PrEP) to People Who Inject Drugs.
    Dubov A; Krakower DS; Rockwood N; Montgomery S; Shoptaw S
    J Gen Intern Med; 2023 Oct; 38(13):2928-2935. PubMed ID: 36964426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of an inner city HIV pre-exposure prophylaxis service tailored to the needs of people who inject drugs.
    Grimshaw C; Boyd L; Smith M; Estcourt CS; Metcalfe R
    HIV Med; 2021 Nov; 22(10):965-970. PubMed ID: 34585494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers.
    Morozova O; Kornilova M; Makarenko O; Antoniak S; Liulchuk M; Varetska O; Dumchev K
    J Int AIDS Soc; 2024 Jul; 27 Suppl 3(Suppl 3):e26319. PubMed ID: 39030884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA.
    Barry MP; Austin EJ; Bhatraju EP; Glick SN; Stekler JD; Tung EL; Hansen RN; Williams EC; Gojic AJ; Pickering EI; Tsui JI
    Harm Reduct J; 2022 Nov; 19(1):121. PubMed ID: 36320005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
    Bazzi AR; Biancarelli DL; Childs E; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Biello KB
    AIDS Patient Care STDS; 2018 Dec; 32(12):529-537. PubMed ID: 30311777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions.
    Bazzi AR; Drainoni ML; Biancarelli DL; Hartman JJ; Mimiaga MJ; Mayer KH; Biello KB
    BMC Public Health; 2019 Jan; 19(1):31. PubMed ID: 30621657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
    Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
    Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery.
    Shaw G; Schaefer R; Schmidt HA; Madden A; Chang J; Mozalevskis A; Msimanga-Radebe B; Mangadan Konath N; Verster A; Baggaley R; Rodolph M; Macdonald V
    Harm Reduct J; 2023 Feb; 20(1):16. PubMed ID: 36782321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of Potential Discriminatory HIV Pre-Exposure Prophylaxis (PrEP) Prescribing Practices for People Who Inject Drugs Among a Small Percentage of Providers in the U.S.
    Pleuhs B; Mistler CB; Quinn KG; Dickson-Gomez J; Walsh JL; Petroll AE; John SA
    J Prim Care Community Health; 2022; 13():21501319211063999. PubMed ID: 35068243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africa-study protocol.
    Medina-Marino A; Bezuidenhout D; Hosek S; Barnabas RV; Atujuna M; Bezuidenhout C; Ngwepe P; Peters RPH; Little F; Celum CL; Daniels J; Bekker LG
    Trials; 2021 Jul; 22(1):489. PubMed ID: 34311754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Use of Pre-Exposure Prophylaxis to Prevent Rapid HIV Transmission Among People Who Inject Drugs in Rural Counties in the United States: A Modeling Study.
    Jacka BP; Nolen S; Bessey SE; Zang X; Goedel WC; Yedinak JL; Marshall BDL
    J Acquir Immune Defic Syndr; 2022 Dec; 91(5):449-452. PubMed ID: 36150038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder.
    Eger WH; Altice FL; Lee J; Vlahov D; Khati A; Osborne S; Wickersham JA; Bohonnon T; Powell L; Shrestha R
    Harm Reduct J; 2022 Oct; 19(1):120. PubMed ID: 36307817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Acting Injectable Human Immunodeficiency Virus Pre-Exposure Prophylaxis Preferred Over Other Modalities Among People Who Inject Drugs: Findings from a Qualitative Study in California.
    Bazzi AR; Valasek CJ; Streuli SA; Vera CF; Harvey-Vera A; Philbin MM; Biello KB; Roth AM; Strathdee SA; Pines HA
    AIDS Patient Care STDS; 2022 Jul; 36(7):254-262. PubMed ID: 35727647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.